Vutrisiran: Warming Before Administration

Vutrisiran: W arming Before Administration

The following information is provided in response to your unsolicited inquiry. It is intended to provide you with a review of the available scientific literature and to assist you in forming your own conclusions in order to make healthcare decisions. This document is not for further dissemination or publication without authorization.

The full Prescribing Information for AMVUTTRA® (vutrisiran) is provided here. Alnylam Pharmaceuticals does not recommend the use of its products in any manner that is inconsistent with the approved Prescribing Information. This resource may contain information that is not in the approved Prescribing Information.

If you are seeking additional scientific information related to Alnylam medicines, you may visit the Alnylam US Medical Affairs website at RNAiScience.com.

SUMMARY

The Prescribing Information (Section 2 Dosage and Administration) provides the following information1:

Administration Instructions: If stored cold, allow the syringe to warm to room temperature for 30 minutes prior to use.

Allowing the syringe to warm to room temperature for 30 minutes prior to use can aid in patient comfort upon administration.
There is no additional information on the administration of vutrisiran without warming to room temperature prior to use.

Updated 14 January 2025

References

1. AMVUTTRA (vutrisiran) Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.


MED-ALL-TTRSC02-2500001 1.0 Approved through Jan 2027

Download PDF